Discover
CRSP
CRISPR Therapeutics AG
55.62
1 x 55.93
2 x 70.40
bid
ask
+
1.08
1.98%
2 @ 06:02 AM
55.19 -0.43 (0.78%)
| Ytd | 6.06% | |
| 1y | 14.66% |
54.56
day range
57.25
44.12
52 week range
78.48
| Open | 54.56 | Prev Close | 54.54 | Low | 54.56 | High | 57.25 | Mkt Cap | 5.48B |
| Vol | 954.48K | Avg Vol | 1.72M | EPS | -6.17 | P/E | N/A | Forward P/E | -14.24 |
| Beta | 1.70 | Short Ratio | 15.40 | Inst. Own | 80.87% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-11 | 50-d Avg | 52.64 | 200-d Avg | 55.56 | 1yr Est | 83.52 |
CRSP News
benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
zacks.com
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Theref
fool.com
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
CRISPR Therapeutics AG continues to pioneer gene-editing through its landmark CASGEVY therapy while
zacks.com
CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors
CRISPR Therapeutics AG (CRSP) closed at $54.92 in the latest trading session, marking a +1.74% move
benzinga.com
Investors Flee Cathie Wood's ARKK ETF As It Trails S&P 500, Nasdaq 100 By Far
Cathie Wood’s ARK Innovation ETF is shedding assets this year as it continues to underperform the te